MRSA is a million-year-old bacterium that kills 19,000 Americans a year, claiming more lives in the US than even AIDS. Though once confined mainly to hospitals, the bacterial infection is now increasingly common outside of medical facilities. Once contracted, MRSA is hard to treat because it's resistant to most antibiotics.
Drug-resistant 'superbugs' hit 20 states, spread worldwide
The bugs, reported by hospitals in more than 20 states, typically strike the critically ill and are fatal in 30% to 60% of cases. Israeli doctors are battling an outbreak in Tel Aviv that has been traced to a patient from northern New Jersey, says Neil Fishman, director of infection control and epidemiology at the University of Pennsylvania and president of the Society of Healthcare Epidemiologists. Ref. Source 7
I believe as time goes on we will see more of these super bugs are scientist in modern medicine have to create more and more new antibiotics to combat infections and other common type viruses that have grown immune to the drugs we use nowadays. I believe this is something that many companies in the fast food industries are doing to people by placing antibiotics into the food they sale the consumers. I know McDonalds is very big in putting antibiotics into their foods.
A USA TODAY examination finds that MRSA infections, particularly outside of health care facilities, are much more common than government statistics suggest. They sicken hundreds of thousands of Americans each year in various ways, from minor skin boils to deadly pneumonia, claiming upward of 20,000 lives. The inability to detect or track cases is confounding efforts by public health officials to develop prevention strategies and keep the bacteria from threatening vast new swaths of the population. Ref. USAToday
Experimental antibiotic treats deadly MRSA infection
A new experimental antibiotic successfully treats the deadly MRSA infection and restores the efficacy of a commonly prescribed antibiotic that has become ineffective against MRSA. Scientists are racing to develop a new class of antibiotics to treat methicillin-resistant Staphylococcus aureus (MRSA) infections, which are responsible for 19,000 deaths annually and represent $3 billion in annual health care costs. Ref. Source 5d.